Breast cancer in men in Cote d'Or (France): epidemiological characteristics, treatments and prognostic factors

被引:8
作者
Dabakuyo, T. S. [1 ,2 ]
Dialla, O. [1 ,2 ]
Gentil, J. [1 ,2 ]
Poillot, M-L [1 ,2 ]
Roignot, P. [3 ]
Cuisenier, J. [4 ]
Arveux, P. [1 ,2 ]
机构
[1] Ctr Georges Francois Leclerc, Breast & Gynaecol Canc Registry Cote dOr, F-21079 Dijon, France
[2] Univ Burgundy, Fac Med, EA 4184, Dijon, France
[3] Ctr Pathol, Dijon, France
[4] Ctr Georges Francois Leclerc, Dept Surg, F-21079 Dijon, France
关键词
breast cancer; epidemiological characteristics; male cancers; prognostic factors; relative survival; treatment; SURVIVAL; POPULATION; CARCINOMA; MANAGEMENT; FEMALE;
D O I
10.1111/j.1365-2354.2012.01365.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
DABAKUYO T. S., DIALLA O., GENTIL J., POILLOT M.-L., ROIGNOT P., CUISENIER J. & ARVEUX P. (2012) European Journal of Cancer Care 21, 809-816 Breast cancer in men in Cote d'Or (France): epidemiological characteristics, treatments and prognostic factors Breast cancer in men is rare, and clinical trials are thus not feasible. This study aimed to describe the epidemiological characteristics, treatment and prognostic factors of breast cancer in men. A population-based study was performed using data from the Cote d'Or breast and gynaecological cancer registry. Data on male breast cancer diagnosed from 1982 to 2008 were provided. Relative survival rates were estimated at 5 years according to the characteristics of the patient and tumour, and treatment. Prognostic factors of survival in men with breast cancer were identified using a generalised linear model. Seventy-five men with invasive breast cancer were registered. Mean age at diagnosis was 66 years. The use of adjuvant chemotherapy (P = 0.013) and hormone therapy (P < 0.0001) increased over time. Relative survival rate at 5 years was 69% for the whole population. Analysis of relative survival according to the treatment showed that survival was longer for patients treated with surgery + radiotherapy + hormone therapy: 89% at 5 years. Scarff, Bloom and Richardson grade was independent prognostic factor of survival. Male breast cancer is a rare disease with a poor prognosis, and diagnosis is often made at an advanced stage. Early diagnosis and better knowledge of the disease would certainly lead to improvements in the prognosis.
引用
收藏
页码:809 / 816
页数:8
相关论文
共 33 条
  • [1] REVIEW OF SURVIVAL ANALYSES PUBLISHED IN CANCER JOURNALS
    ALTMAN, DG
    DESTAVOLA, BL
    LOVE, SB
    STEPNIEWSKA, KA
    [J]. BRITISH JOURNAL OF CANCER, 1995, 72 (02) : 511 - 518
  • [2] Is male breast cancer similar or different than female breast cancer?
    Anderson, WF
    Althuis, MD
    Brinton, LA
    Devesa, SS
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 83 (01) : 77 - 86
  • [3] [Anonymous], CA CANC J CLIN, DOI DOI 10.3322/CAAC.20107
  • [4] [Anonymous], 1997, International Union against Cancer (UICC). TNM Classification of Malignant Tumours
  • [5] Breast cancer in the male: a report of 19 cases
    Benchellal, Z
    Wagner, A
    Harchaoui, Y
    Huten, N
    Body, G
    [J]. ANNALES DE CHIRURGIE, 2002, 127 (08): : 619 - 623
  • [6] Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study
    Berrino, Franco
    De Angelis, Roberta
    Sant, Milena
    Rosso, Stefano
    Lasota, Magdalena B.
    Coebergh, Jan W.
    Santaquilani, Mariano
    [J]. LANCET ONCOLOGY, 2007, 8 (09) : 773 - 783
  • [7] Black R J, 1998, IARC Sci Publ, P13
  • [8] Male breast cancer: A report of 127 cases at a Moroccan institution
    Bourhafour M.
    Belbaraka R.
    Souadka A.
    M'Rabti H.
    Tijami F.
    Errihani H.
    [J]. BMC Research Notes, 4 (1)
  • [9] Invasive carcinomas of the male breast: a morphologic study of the distribution of histologic subtypes and metastatic patterns in 778 cases
    Burga, Ana M.
    Fadare, Oluwole
    Lininger, Ruth A.
    Tavassoli, Fattaneh A.
    [J]. VIRCHOWS ARCHIV, 2006, 449 (05) : 507 - 512
  • [10] Male breast cancer: Results of the treatments and prognostic factors in 397 cases
    Cutuli, B
    Lacroze, M
    Dilhuydy, JM
    Velten, M
    DeLafontan, B
    Marchal, C
    Resbeut, M
    Graic, Y
    Campana, F
    MonchoBernier, V
    DeGislain, C
    Tortochaux, J
    Cuillere, JC
    RemeSaumon, M
    NGuyen, TD
    Lesaunier, F
    LeSimple, T
    Gamelin, E
    Hery, M
    Berlie, J
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A (12) : 1960 - 1964